PharmaCorp Rx completes fourth pharmacy acquisition for $2.4 million

SASKATOON - PharmaCorp Rx Inc. (TSXV:PCRX), a pharmaceutical retailer with annual revenues of $705.85 million and a market capitalization of $1.01 billion, has acquired a pharmacy business in Western Canada for $2.4 million in cash, the company announced Thursday.

The transaction represents PharmaCorp’s fourth pharmacy acquisition and was completed in conjunction with its strategic alliance with PharmaChoice Canada Inc. The company maintains a healthy current ratio of 2.38, indicating strong ability to fund its expansion strategy.

"We’re grateful for the trust placed in us through this acquisition and proud to welcome this pharmacy into the PharmaCorp family," said Al Simpson, Executive Chair of PharmaCorp.

The company did not disclose the specific location or name of the acquired pharmacy, describing it only as located in Western Canada. The transaction was conducted at arm’s length, meaning the parties were unrelated and negotiated independently.

PharmaCorp currently operates four PharmaChoice-branded pharmacies in Canada. According to the company, it plans to continue acquiring both PharmaChoice-branded pharmacies and independently owned non-PharmaChoice pharmacies, with the latter to be operated under the PharmaChoice banner following acquisition.

The acquisition follows a previous announcement on June 26, 2025, when the company first disclosed its intention to purchase the pharmacy.

PharmaCorp shares trade on the TSX Venture Exchange under the symbol PCRX. According to InvestingPro analysis, the stock appears undervalued with strong growth potential, supported by multiple positive indicators. Get access to detailed financial analysis and 7 additional ProTips for PCRX with an InvestingPro subscription.

The information in this article is based on a company press release statement and enhanced with financial data from InvestingPro.

In other recent news, Pacira Pharmaceuticals Inc. reported its Q2 2025 earnings on August 5, showing a mixed financial performance. The company announced a narrowing of its full-year revenue guidance to a range between $730 million and $750 million. These developments come as investors assess the implications of the updated financial outlook. The earnings announcement led to a slight decline in Pacira’s stock during regular trading hours. However, the stock showed a positive shift in aftermarket trading, increasing by 3.53%. This earnings report is a key focus for investors as they evaluate Pacira’s financial health and future prospects. The company’s revenue guidance adjustment is particularly significant, as it provides insight into expected performance for the remainder of the year. Investors may also be considering the broader market context and how Pacira’s financial results align with industry trends.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.